Nadeem Rais Explains: A Clinical Comparison of AntiPlatelets vs AntiCoagulants
Nadeem Rais, Clinical Pharmacist at NMC Healthcare, shared a post on LinkedIn:
“AntiPlatelets vs AntiCoagulants
Blood clot prevention is not one-size-fits-all. Two major drug classes act at different stages of thrombosis.
• 𝗔𝗻𝘁𝗶𝗣𝗹𝗮𝘁𝗲𝗹𝗲𝘁𝘀
Drugs that inhibit platelet activation and aggregation.
𝙈𝙚𝙘𝙝𝙖𝙣𝙞𝙨𝙢 𝙊𝙛 𝘼𝙘𝙩𝙞𝙤𝙣: They block platelet-to-platelet interaction at sites of vascular injury.
𝘾𝙤𝙢𝙢𝙤𝙣 𝘿𝙧𝙪𝙜𝙨:
▪ Aspirin (Acetylsalicylic Acid)
▪ Clopidogrel (Adenosine Diphosphate Receptor Inhibitor)
▪ Prasugrel (P2Y12 Receptor Inhibitor)
▪ Ticagrelor (Reversible P2Y12 Inhibitor)
𝙈𝙖𝙟𝙤𝙧 𝙄𝙣𝙙𝙞𝙘𝙖𝙩𝙞𝙤𝙣𝙨:
▪ Myocardial Infarction (Heart Attack)
▪ Ischemic Stroke
▪ Post Percutaneous Coronary Intervention (PCI)
𝙏𝙝𝙧𝙤𝙢𝙗𝙪𝙨 𝙏𝙮𝙥𝙚: Platelet-rich clots. Also called white clots.
𝙈𝙤𝙣𝙞𝙩𝙤𝙧𝙞𝙣𝙜: Routine laboratory monitoring is usually not required.
• 𝗔𝗻𝘁𝗶𝗖𝗼𝗮𝗴𝘂𝗹𝗮𝗻𝘁𝘀
Drugs that inhibit clotting factors in the coagulation cascade.
𝙈𝙚𝙘𝙝𝙖𝙣𝙞𝙨𝙢 𝙊𝙛 𝘼𝙘𝙩𝙞𝙤𝙣: They slow or stop fibrin formation.
𝘾𝙤𝙢𝙢𝙤𝙣 𝘿𝙧𝙪𝙜𝙨:
▪ Heparin (Indirect Thrombin Inhibitor)
▪ Warfarin (Vitamin K Antagonist)
▪ Dabigatran (Direct Thrombin Inhibitor)
▪ Rivaroxaban (Factor Xa Inhibitor)
▪ Apixaban (Factor Xa Inhibitor)
𝙈𝙖𝙟𝙤𝙧 𝙄𝙣𝙙𝙞𝙘𝙖𝙩𝙞𝙤𝙣𝙨:
▪ Deep Vein Thrombosis (DVT)
▪ Pulmonary Embolism (PE)
▪ Atrial Fibrillation (AF)
𝙏𝙝𝙧𝙤𝙢𝙗𝙪𝙨 𝙏𝙮𝙥𝙚: Fibrin-rich clots. Also called red clots.
𝙈𝙤𝙣𝙞𝙩𝙤𝙧𝙞𝙣𝙜:
▪ Warfarin requires International Normalized Ratio (INR) monitoring
▪ Direct Oral Anticoagulants usually do not require routine monitoring
𝗞𝗲𝘆 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲
→ AntiPlatelets act early at platelet level
→ AntiCoagulants act later at coagulation factor level
Credit: Federation of Clinical Pharmacists in India (FCPI)
Repost to share with your peers
Follow Nadeem Rais, PhD for more”
Follow the latest in Hemostasis Today.
-
Jul 20, 2026, 08:08Ifeanyichukwu Ifechidere: COVID-19 Changed Our Understanding of Coagulation
-
Jul 20, 2026, 07:27Vonwicks Czelestakov Onyango: The Anticoagulation Dilemma in Ulcerative Colitis
-
Jul 20, 2026, 06:14Elen Avetisyan: A Memorable Week of Science and Collaboration at ISTH 2026
-
Jul 19, 2026, 16:59Rupam Manna: Not All Portal Vein Involvement in HCC Is the Same
-
Jul 19, 2026, 16:58Axel Cangas: Exploring the Future of Hemophilia Care at ISTH 2026
-
Jul 19, 2026, 16:58Aviva Schwartz: Air Pollution and Women’s Hematological Health in the Spotlight at ISTH 2026
-
Jul 19, 2026, 16:56Lola Sepot-Boucherit: Reimagining the Future of Rare Bleeding Disorders at ISTH 2026
-
Jul 19, 2026, 16:54Belén de la Morena Barrio: Presenting Our Research on Long-Read Sequencing for Genetic Diagnosis at ISTH 2026
-
Jul 19, 2026, 16:52Shamee Shastry: Sometimes the Answer is Not in the Test Tube Alone, but at the Patient’s Bedside